Acute coronary syndrome and coronary artery disease in wild-type transthyretin amyloid cardiomyopathy: a DIAMOND sub-study

Journal of Cardiovascular Medicine 2026 Open access

Read full text
Authors: Laura De Michieli, Giacomo Tini, Alessia Argirò, Paolo Milani, Mattia Zampieri, Angelo Giuseppe Caponetti, Francesca Fabris, Andrea Foli, Carlotta Mazzoni, Christian Gagliardi, Simone Longhi, Giulia Saturi
+38 more Giuseppe Vergaro, Alberto Aimo, Ilaria Della Ricca, Aldostefano Porcari, Matteo Serenelli, Gioele Fabbri, Giuseppe Palmiero, Giuseppe Ciliberti, Giulio Sinigiani, Giulia Lorenzoni, Samuela Carigi, Eugenio Sessarego, Giulia Elena Mandoli, Giulia Ricci Lucchi, Valeria Rella, Enrico Monti, Elisa Gardini, Michela Bartolotti, Lia Crotti, Elisa Merli, Matteo Cameli, Francesca Marzo, Federico Guerra, Giuseppe Limongelli, Stefano Perlini, Laura Piera Obici, Federico Perfetto, Camillo Autore, Italo Porto, Gianfranco Sinagra, Marco Merlo, Beatrice Musumeci, Michele Emdin, Elena Biagini, Giovanni O. Palladini, Marco Canepa, Alberto Cipriani, Francesco Cappelli
DOI: 10.2459/jcm.0000000000001844
Cited by: 0
References: 7

Abstract

BACKGROUND: Patients with wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) often have cardiovascular comorbidities, including acute coronary syndrome (ACS) and coronary artery disease (CAD). RESULTS AND MAJOR FINDINGS: At baseline, 9% of patients had a history of ACS and this was associated with increased risk of adverse outcomes, while this was not the case for obstructive CAD without ACS. Further prospective studies are needed to corroborate these findings.

Fields of Study & Subjects

Amyloidosis: Diagnosis Treatment Outcomes Cardiac electrophysiology and arrhythmias Alzheimer's disease research and treatments

Publication details

Journal / source
Journal of Cardiovascular Medicine
Volume
27
Issue
2
Pages
171–175
Publication date
30 January 2026
Language
EN